157 related articles for article (PubMed ID: 31466125)
1. Elevated Fatty Liver Index as a Risk Factor for All-Cause Mortality in Human Immunodeficiency Virus-Hepatitis C Virus-Coinfected Patients (ANRS CO13 HEPAVIH Cohort Study).
Barré T; Protopopescu C; Bani-Sadr F; Piroth L; Rojas Rojas T; Salmon-Ceron D; Wittkop L; Esterle L; Sogni P; Lacombe K; Chas J; Zaegel O; Chaix ML; Miailhes P; Serfaty L; Marcellin F; Carrieri MP;
Hepatology; 2020 Apr; 71(4):1182-1197. PubMed ID: 31466125
[TBL] [Abstract][Full Text] [Related]
2. Increased liver stiffness is associated with mortality in HIV/HCV coinfected subjects: The French nationwide ANRS CO13 HEPAVIH cohort study.
Shili-Masmoudi S; Sogni P; de Ledinghen V; Esterle L; Valantin MA; Poizot-Martin I; Simon A; Rosenthal E; Lacombe K; Pialoux G; Bouchaud O; Gervais-Hasenknoff A; Goujard C; Piroth L; Zucman D; Dominguez S; Raffi F; Alric L; Bani-Sadr F; Lascoux-Combe C; Garipuy D; Miailhes P; Vittecoq D; Duvivier C; Aumaître H; Neau D; Morlat P; Dabis F; Salmon D; Wittkop L;
PLoS One; 2019; 14(1):e0211286. PubMed ID: 30682180
[TBL] [Abstract][Full Text] [Related]
3. Increased mortality in HIV/HCV-coinfected compared to HCV-monoinfected patients in the DAA era due to non-liver-related death.
Chalouni M; Pol S; Sogni P; Fontaine H; Lacombe K; Marc-Lacombe J; Esterle L; Dorival C; Bourlière M; Bani-Sadr F; de Ledinghen V; Zucman D; Larrey D; Salmon D; Carrat F; Wittkop L;
J Hepatol; 2021 Jan; 74(1):37-47. PubMed ID: 32798585
[TBL] [Abstract][Full Text] [Related]
4. Cannabis use and reduced risk of elevated fatty liver index in HIV-HCV co-infected patients: a longitudinal analysis (ANRS CO13 HEPAVIH).
Barré T; Rojas Rojas T; Lacombe K; Protopopescu C; Poizot-Martin I; Nishimwe ML; Zucman D; Esterle L; Billaud E; Aumaitre H; Bouchaud O; Rey D; Piroth L; Salmon-Ceron D; Wittkop L; Sogni P; Carrieri MP; Serfaty L; Marcellin F
Expert Rev Anti Infect Ther; 2021 Sep; 19(9):1147-1156. PubMed ID: 33538612
[No Abstract] [Full Text] [Related]
5. All-oral Direct-acting Antiviral Regimens in HIV/Hepatitis C Virus-coinfected Patients With Cirrhosis Are Efficient and Safe: Real-life Results From the Prospective ANRS CO13-HEPAVIH Cohort.
Sogni P; Gilbert C; Lacombe K; Piroth L; Rosenthal E; Miailhes P; Gervais A; Esterle L; Chas J; Poizot-Martin I; Dominguez S; Simon A; Morlat P; Neau D; Zucman D; Bouchaud O; Lascoux-Combe C; Bani-Sadr F; Alric L; Goujard C; Vittecoq D; Billaud E; Aumaître H; Boué F; Valantin MA; Dabis F; Salmon D; Wittkop L
Clin Infect Dis; 2016 Sep; 63(6):763-770. PubMed ID: 27317796
[TBL] [Abstract][Full Text] [Related]
6. Human Immunodeficiency Virus/Hepatitis C Virus (HCV) Co-infected Patients With Cirrhosis Are No Longer at Higher Risk for Hepatocellular Carcinoma or End-Stage Liver Disease as Compared to HCV Mono-infected Patients.
Salmon-Ceron D; Nahon P; Layese R; Bourcier V; Sogni P; Bani-Sadr F; Audureau E; Merchadou L; Dabis F; Wittkop L; Roudot-Thoraval F;
Hepatology; 2019 Sep; 70(3):939-954. PubMed ID: 30569448
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of direct-acting antiviral regimens in HIV/HCV-co-infected patients - French ANRS CO13 HEPAVIH cohort.
Piroth L; Wittkop L; Lacombe K; Rosenthal E; Gilbert C; Miailhes P; Carrieri P; Chas J; Poizot-Martin I; Gervais A; Dominguez S; Neau D; Zucman D; Billaud E; Morlat P; Aumaitre H; Lascoux-Combe C; Simon A; Bouchaud O; Teicher E; Bani-Sadr F; Alric L; Vittecoq D; Boué F; Duvivier C; Valantin MA; Esterle L; Dabis F; Sogni P; Salmon D;
J Hepatol; 2017 Jul; 67(1):23-31. PubMed ID: 28235612
[TBL] [Abstract][Full Text] [Related]
8. Daily cannabis and reduced risk of steatosis in human immunodeficiency virus and hepatitis C virus-co-infected patients (ANRS CO13-HEPAVIH).
Nordmann S; Vilotitch A; Roux P; Esterle L; Spire B; Marcellin F; Salmon-Ceron D; Dabis F; Chas J; Rey D; Wittkop L; Sogni P; Carrieri P;
J Viral Hepat; 2018 Feb; 25(2):171-179. PubMed ID: 28984055
[TBL] [Abstract][Full Text] [Related]
9. Protective effect of coffee consumption on all-cause mortality of French HIV-HCV co-infected patients.
Carrieri MP; Protopopescu C; Marcellin F; Rosellini S; Wittkop L; Esterle L; Zucman D; Raffi F; Rosenthal E; Poizot-Martin I; Salmon-Ceron D; Dabis F; Spire B;
J Hepatol; 2017 Dec; 67(6):1157-1167. PubMed ID: 28942916
[TBL] [Abstract][Full Text] [Related]
10. Direct, indirect and total effect of HIV coinfection on the risk of non-liver-related cancer in hepatitis C virus-infected patients treated by direct-acting antivirals: a mediation analysis.
Chalouni M; Pol S; Sogni P; Fontaine H; Lacombe K; Lacombe JM; Esterle L; Dorival C; Bourlière M; Bani-Sadr F; de Ledinghen V; Zucman D; Larrey D; Salmon D; Carrat F; Wittkop L; ; Martinez V
HIV Med; 2021 Nov; 22(10):924-935. PubMed ID: 34402547
[TBL] [Abstract][Full Text] [Related]
11. Sleep disturbances in HIV-HCV coinfected patients: indications for clinical management in the HCV cure era (ANRS CO13 HEPAVIH cohort).
Costa M; Rojas TR; Lacoste D; Villes V; Aumaitre H; Protopopescu C; Yaya I; Wittkop L; Krause J; Salmon-Céron D; Marcellin F; Sogni P; Carrieri MP;
Eur J Gastroenterol Hepatol; 2019 Dec; 31(12):1508-1517. PubMed ID: 31094856
[TBL] [Abstract][Full Text] [Related]
12. Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus.
Berenguer J; Alvarez-Pellicer J; Martín PM; López-Aldeguer J; Von-Wichmann MA; Quereda C; Mallolas J; Sanz J; Tural C; Bellón JM; González-García J;
Hepatology; 2009 Aug; 50(2):407-13. PubMed ID: 19575364
[TBL] [Abstract][Full Text] [Related]
13. Regression of liver stiffness after sustained hepatitis C virus (HCV) virological responses among HIV/HCV-coinfected patients.
ANRS CO13 HEPAVIH Cohort
AIDS; 2015 Sep; 29(14):1821-30. PubMed ID: 26372388
[TBL] [Abstract][Full Text] [Related]
14. Chronic hepatitis C virus infection is associated with all-cause and liver-related mortality in a cohort of HIV-infected patients with alcohol problems.
Fuster D; Cheng DM; Quinn EK; Nunes D; Saitz R; Samet JH; Tsui JI
Addiction; 2014 Jan; 109(1):62-70. PubMed ID: 24112091
[TBL] [Abstract][Full Text] [Related]
15. Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study.
Carrat F; Fontaine H; Dorival C; Simony M; Diallo A; Hezode C; De Ledinghen V; Larrey D; Haour G; Bronowicki JP; Zoulim F; Asselah T; Marcellin P; Thabut D; Leroy V; Tran A; Habersetzer F; Samuel D; Guyader D; Chazouilleres O; Mathurin P; Metivier S; Alric L; Riachi G; Gournay J; Abergel A; Cales P; Ganne N; Loustaud-Ratti V; D'Alteroche L; Causse X; Geist C; Minello A; Rosa I; Gelu-Simeon M; Portal I; Raffi F; Bourliere M; Pol S;
Lancet; 2019 Apr; 393(10179):1453-1464. PubMed ID: 30765123
[TBL] [Abstract][Full Text] [Related]
16. Short article: Fatigue in the long term after HCV treatment in HIV-HCV-coinfected patients: functional limitations persist despite viral clearance in patients exposed to peg-interferon/ribavirin-containing regimens (ANRS CO13-HEPAVIH cohort).
Marcellin F; Protopopescu C; Poizot-Martin I; Miailhes P; Esterle L; Wittkop L; Spire B; Bocquier A; Salmon-Ceron D; Dabis F; Carrieri MP;
Eur J Gastroenterol Hepatol; 2016 Sep; 28(9):1003-7. PubMed ID: 27177169
[TBL] [Abstract][Full Text] [Related]
17. Psychiatric and substance use disorders in HIV/hepatitis C virus (HCV)-coinfected patients: does HCV clearance matter? [Agence Nationale de Recherche sur le SIDA et les Hépatites Virales (ANRS) HEPAVIH CO13 cohort].
Michel L; Lions C; Winnock M; Lang JP; Loko MA; Rosenthal E; Marchou B; Valantin MA; Morlat P; Roux P; Sogni P; Spire B; Poizot-Martin I; Lacombe K; Lascoux-Combe C; Duvivier C; Neau D; Dabis F; Salmon-Ceron D; Carrieri MP;
HIV Med; 2016 Nov; 17(10):758-765. PubMed ID: 27187027
[TBL] [Abstract][Full Text] [Related]
18. Prevalence and Predictors of Hepatic Steatosis in Patients with HIV/HCV Coinfection and the Impact of HCV Eradication.
Chromy D; Mandorfer M; Bucsics T; Schwabl P; Bauer D; Scheiner B; Schmidbauer C; Lang GF; Szekeres T; Ferenci P; Trauner M; Reiberger T
AIDS Patient Care STDS; 2019 May; 33(5):197-206. PubMed ID: 31067123
[TBL] [Abstract][Full Text] [Related]
19. Risk of severe clinical events after sustained virological response following direct-acting antiviral therapy in HIV and hepatitis C virus coinfected participants.
Chalouni M; Wittkop L; Bani-Sadr F; Lacombe K; Esterle L; Gilbert C; Miailhes P; Zucman D; Valantin MA; Brégigeon-Ronot S; Morlat P; Billaud E; Piroth L; Naqvi A; Sogni P; Salmon D;
HIV Med; 2021 Oct; 22(9):791-804. PubMed ID: 34212476
[TBL] [Abstract][Full Text] [Related]
20. Liver stiffness and fibrosis-4 alone better predict liver events compared with aspartate aminotransferase to platelet ratio index in a cohort of human immunodeficiency virus and hepatitis C virus co-infected patients from ANRS CO13 HEPAVIH cohort.
Chalouni M; Sogni P; Miailhes P; Lacombe K; Poizot-Martin I; Chas J; Vittecoq D; Neau D; Aumaitre H; Alric L; Piroth L; Bouchaud O; Katlama C; Morlat P; Lascoux-Combe C; Gervais A; Naqvi A; Rosenthal E; Garipuy D; Barange K; Esterle L; Salmon D; Wittkop L;
Eur J Gastroenterol Hepatol; 2019 Nov; 31(11):1387-1396. PubMed ID: 31033848
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
